# A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever

> **NCT03830684** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Baicalein Tablets 400mg
- **DRUG:** Baicalein Tablets 600mg
- **DRUG:** blank control 0mg

## Key facts

- **NCT ID:** NCT03830684
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-10-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03830684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03830684, "A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03830684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*